Sarvajit CHAKRAVARTY,Dhananjay PENDHARKAR,Dilip V. JARIKOTE,Bhausaheb B. BHAGWAT,Anil K. AGARWAL,Brahmam PUJALA,Sreekanth A. RAMACHANDRAN,Sagar PATNI
申请号：
US16632213
公开号：
US20200171030A1
申请日:
2019.01.17
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present disclosure generally relates to the compounds that exhibits protein kinase inhibitory activity. Specifically, the present disclosure provides compounds of formula (I) that exhibits dual inhibitory activity against ALK5 and P38A MAP kinase. The present disclosure also provides process(es) for preparation of such compounds, pharmaceutical compositions containing one or a combination of these compounds, and methods of treatment of conditions associated with excessive activity of any or a combination of transforming growth factor-beta (TGFβ) and p38 mitogen-activated protein kinase (MAPK) utilizing these compounds. An aspect of the present disclosure provides compounds of Formula (I):and pharmaceutically acceptable salt, polymorph, solvate or stereoisomer thereof that exhibit dual inhibitory activity against ALK5 and P38 alpha.
